CA-GENERAL-ATOMICS
General Atomics Aeronautical Systems, Inc. (GA-ASI) concluded a series of flight demonstrations using its MQ-9 Guardian Remotely Piloted Aircraft System (RPAS) on December 19, 2019. The demonstrations showcased the maritime surveillance capabilities of the MQ-9, and the GA-ASI-developed Detect and Avoid (DAA) system for traffic-deconfliction in civil airspace. The flights were sponsored by the Hellenic Air Force (HAF) and the Hellenic Coast Guard (HCG) and staged out of Larissa Air Base in Greece. The flights were performed for an audience of European military and civilian representatives.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200106005949/en/
“We were honored to have the HAF’s and the HCG’s support for these flight demonstrations with our MQ-9,” said Linden Blue, CEO, GA-ASI. “The MQ-9 RPAS is already a strategic asset for NATO countries, providing mission persistence and interoperability between allies. We showcased MQ-9’s maritime surveillance and the civil airspace integration capabilities for our European customers.” The MQ-9 configuration demonstrated is operational in the U.S.
Currently GA-ASI aircraft systems support the Italian Air Force, the UK Royal Air Force, the French Air Force, and the Spanish Air Force. The Ministry of Defence for the Netherlands has selected MQ-9 for the Royal Netherlands Air Force, and the Government of Belgium has approved Belgian Defense to negotiate the acquisition of GA-ASI’s MQ-9B. In early December, the Australian Government announced selection of MQ-9B for the Australian Defence Force under Project Air 7003. GA-ASI RPAS are operated by the U.S. Air Force, U.S. Army, U.S. Marine Corps, U.S. Department of Homeland Security and NASA.
“The advanced capabilities of these aircraft are striking. Through the 10 days of demonstrations, the country of Greece has seen the value of MQ-9s for maritime patrol and EEZ monitoring, border surveillance, support for search and rescue efforts, and over-watch of forest fire response efforts,” said an HAF official.
The DAA system consists of an air-to-air radar integrated with Traffic Alert and Collision Avoidance System (TCAS II), and Automatic Dependent Surveillance-Broadcast (ADS-B). The DAA system enables safe flight of an MQ-9 in civil airspace, and can even detect air traffic that is not actively transmitting its position.
The MQ-9 also demonstrated a multi-mode, maritime surface-search radar, and High-Definition/Full-Motion Video Optical and Infrared sensor. This sensor suite enables real-time detection and identification of large and small surface vessels in all-weather at long ranges, 360 degrees around the aircraft. The featured Raytheon SeaVue surface-search radar provided continuous tracking of maritime targets and correlation of AIS transmitters with radar detections. The Inverse Synthetic Aperture Radar (ISAR) mode facilitates classification of vessels which are beyond optical sensor range.
For the demonstration, GA-ASI partnered with SES, a leading satellite communications (SATCOM) operator and managed services provider, with over 70 satellites in Geostationary Orbit (GEO) and Medium Earth Orbit (MEO). SES provided the GEO satellite connectivity that enabled the MQ-9 to operate securely with a high capacity datalink, enabling real-time transmission of sensor data from the aircraft, and extending its effective operational range far beyond that of “line-of-sight” datalinks.
“With our global satellite fleet, SES has been supporting the critical needs of GA-ASI and their government customers who have operated these aircraft for close to two decades,” said Nicole Robinson, Senior Vice President, Global Government at SES Networks. “We were proud to support this demonstration effort for the Hellenic Air Force as part of our long-standing relationship with General Atomics.”
Hi-resolution images from the demonstration are available to qualified media outlets from the GA-ASI and HAF media contact list. More information about the event is available at www.ga-asi.com/european-maritime-demo .
About GA-ASI
General Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable Remotely Piloted Aircraft (RPA) systems, radars, and electro-optic and related mission systems, including the Predator® RPA series and the Lynx® Multi-mode Radar. With more than six million flight hours, GA-ASI provides long-endurance, mission-capable aircraft with integrated sensor and data link systems required to deliver persistent flight that enables situational awareness and rapid strike. The company also produces a variety of ground control stations and sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas. For more information, visit www.ga-asi.com .
Predator and Lynx are registered trademarks of General Atomics Aeronautical Systems, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200106005949/en/
Contact:
Steven Henden General Atomics Aeronautical Systems, Inc. +1 (858) 524-8101 ASI-MediaRelations@ga-asi.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
